Among those celebrating today’s agreement on a voluntary rebate scheme for branded medicines in the UK, there are dissenting voices, including a group representing manufac
EVERSANA has taken another step forwards in its effort to put generative artificial intelligence (GenAI) at the heart of the pharma industry’s processes.
After months of wrangling, an agreement has finally been reached on a successor to the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), the system of reve
The European Commission has approved Almirall’s lebrikizumab as Ebglyss for the treatment of moderate-to-severe atopic dermatitis (AD), with an EU rollout set to start in
Eli Lilly has followed Novo Nordisk in announcing a big investment in its manufacturing network, intended to meet anticipated strong future demand for diabetes and obesity
Already a mainstay of prostate cancer therapy, Pfizer and Astellas’ Xtandi has picked up a new approval in the US that could reinvigorate the drug, even as it approaches i
ESMO 2024 was chock full of oncological data, diverse presentations providing hope across the cancer spectrum from breast and lung to unmet needs in colorectal and bladder.